Neoadjuvant CAN-2409 plus Prodrug in Combination with Standard of Care Chemoradiation for Borderline Resectable Pancreatic Adenocarcinoma

Neoadjuvant CAN-2409 plus Prodrug in Combination with Standard of Care Chemoradiation for Borderline Resectable Pancreatic Adenocarcinoma | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Brief Communication Neoadjuvant CAN-2409 plus Prodrug in Combination with Standard of Care Chemoradiation for Borderline Resectable Pancreatic Adenocarcinoma William Nichols, Andrea Manzanera, Mark Bloomston, Vanessa Rosas-Camargo, and 5 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-5183420/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Pancreatic ductal adenocarcinoma (PDAC) remains a deadly form of cancer because of its cold and immunosuppressive tumor microenvironment. A previous phase 1b clinical trial showed that treatment with CAN-2409 plus valacyclovir induced a significant increase in tumor infiltrating lymphocytes in the tumor. We report the findings of a randomized controlled phase 2a clinical trial of CAN-2409 plus valacyclovir with standard of care (SoC) for borderline resectable PDAC. Estimated median overall survival was 28.8 months in the CAN-2409 group versus 12.5 months in controls. There was systemic immune activation and formation of lymphocyte aggregates that resemble tertiary lymphoid structures in the test arm, but not in controls. ClinicalTrials.gov registration: NCT02446093 Biological sciences/Cancer/Gastrointestinal cancer/Pancreatic cancer Health sciences/Medical research/Drug development Biological sciences/Immunology/Immunotherapy/Immunization Full Text Additional Declarations Yes there is potential Competing Interest. WGN, AM, SR, JD, FB, PPT are employed by Candel Therapeutics. Supplementary Files PaTK02SupplementalFiguresTablesFinal.pdf Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-5183420","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Brief Communication","associatedPublications":[],"authors":[{"id":361546047,"identity":"c8aca23d-0fac-42d7-9a90-ecd2a3e0e7d4","order_by":0,"name":"William Nichols","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA3klEQVRIiWNgGAWjYFACxgZmBgYLBn4QmwfIIFaLBINkA1iLhARR9oC1GBwgVot8dHPj54IKCXvj44efPXhTIVFncID54aMbeLQY3jnYLD3jjETitjNp5oZzzkhISDawGRvn4NMyI7GNmbdNIsHsBoOZNJAhwc/AwyZNjBZ74xns36R5/0lIsBHSIi8B0cK4QYIHaEsDEbYYSCQ2S/MA/TLjTE6Z5JxjEpIzmwn4RX5G+sPPPBU29vztx7dJvKmx4Tc43vzwMV5bDmAIMeNRDralgYCCUTAKRsEoGAUMAF/0P+cBKCSaAAAAAElFTkSuQmCC","orcid":"","institution":"Candel Therapeutics","correspondingAuthor":true,"prefix":"","firstName":"William","middleName":"","lastName":"Nichols","suffix":""},{"id":361546048,"identity":"ad9f1c2f-a765-4903-a9da-72134c956572","order_by":1,"name":"Andrea Manzanera","email":"","orcid":"","institution":"Candel Therapeutics","correspondingAuthor":false,"prefix":"","firstName":"Andrea","middleName":"","lastName":"Manzanera","suffix":""},{"id":361546049,"identity":"8b6b6fee-a990-4545-86b9-cd4ab1cbfdba","order_by":2,"name":"Mark Bloomston","email":"","orcid":"","institution":"Lee Health Regional Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Mark","middleName":"","lastName":"Bloomston","suffix":""},{"id":361546050,"identity":"0f88c168-a85b-4b33-9af9-7b7331e88834","order_by":3,"name":"Vanessa Rosas-Camargo","email":"","orcid":"","institution":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","correspondingAuthor":false,"prefix":"","firstName":"Vanessa","middleName":"","lastName":"Rosas-Camargo","suffix":""},{"id":361546051,"identity":"61a103fb-bc77-4eba-9516-13abd7663fe7","order_by":4,"name":"Fidel David Huitzil-Melendez","email":"","orcid":"","institution":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","correspondingAuthor":false,"prefix":"","firstName":"Fidel","middleName":"David","lastName":"Huitzil-Melendez","suffix":""},{"id":361546052,"identity":"a83e8d95-e4ae-4466-af8e-1560a2626e56","order_by":5,"name":"Shangbang Rao","email":"","orcid":"","institution":"Candel Therapeutics","correspondingAuthor":false,"prefix":"","firstName":"Shangbang","middleName":"","lastName":"Rao","suffix":""},{"id":361546053,"identity":"66e7ce28-66a9-4162-9fe2-2f7d14e6b5f4","order_by":6,"name":"Jessica Dwyer","email":"","orcid":"","institution":"Candel Therapeutics","correspondingAuthor":false,"prefix":"","firstName":"Jessica","middleName":"","lastName":"Dwyer","suffix":""},{"id":361546055,"identity":"817c3b5a-f7f5-434b-9d04-da2335750359","order_by":7,"name":"Francesca Barone","email":"","orcid":"https://orcid.org/0000-0002-5287-9614","institution":"Candel Therapeutics","correspondingAuthor":false,"prefix":"","firstName":"Francesca","middleName":"","lastName":"Barone","suffix":""},{"id":361546059,"identity":"19218f99-0939-4303-b9f2-1101ac02c9ef","order_by":8,"name":"Paul Tak","email":"","orcid":"https://orcid.org/0000-0002-3532-5409","institution":"Candel Therapeutics","correspondingAuthor":false,"prefix":"","firstName":"Paul","middleName":"","lastName":"Tak","suffix":""}],"badges":[],"createdAt":"2024-09-30 21:20:27","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-5183420/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-5183420/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":71205195,"identity":"baa3156c-e2e6-4f09-8c32-2df1160b106e","added_by":"auto","created_at":"2024-12-12 07:03:38","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":352757,"visible":true,"origin":"","legend":"","description":"","filename":"Pancreasmanuscripttextandfigures.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5183420/v1_covered_bf1914d7-a764-483f-a608-6e939d9eea8d.pdf"},{"id":68330857,"identity":"596b2081-d2f5-43e3-a3a7-eb5c766af835","added_by":"auto","created_at":"2024-11-06 07:07:29","extension":"pdf","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":2764954,"visible":true,"origin":"","legend":"","description":"","filename":"PaTK02SupplementalFiguresTablesFinal.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5183420/v1/f5482a5dd9dda5191f950623.pdf"}],"financialInterests":"\u003cb\u003eYes\u003c/b\u003e there is potential Competing Interest.\nWGN, AM, SR, JD, FB, PPT are employed by Candel Therapeutics.","formattedTitle":"Neoadjuvant CAN-2409 plus Prodrug in Combination with Standard of Care Chemoradiation for\r\nBorderline Resectable Pancreatic Adenocarcinoma","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-5183420/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-5183420/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003ePancreatic ductal adenocarcinoma (PDAC) remains a deadly form of cancer because of its cold and immunosuppressive tumor microenvironment. A previous phase 1b clinical trial showed that treatment with CAN-2409 plus valacyclovir induced a significant increase in tumor infiltrating lymphocytes in the tumor. We report the findings of a randomized controlled phase 2a clinical trial of CAN-2409 plus valacyclovir with standard of care (SoC) for borderline resectable PDAC. Estimated median overall survival was 28.8 months in the CAN-2409 group versus 12.5 months in controls. There was systemic immune activation and formation of lymphocyte aggregates that resemble tertiary lymphoid structures in the test arm, but not in controls.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eClinicalTrials.gov registration:\u003c/strong\u003e NCT02446093\u003c/p\u003e","manuscriptTitle":"Neoadjuvant CAN-2409 plus Prodrug in Combination with Standard of Care Chemoradiation for\nBorderline Resectable Pancreatic Adenocarcinoma","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-11-06 07:07:24","doi":"10.21203/rs.3.rs-5183420/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"07a9e4fc-6be3-4da1-a7da-d360de5548da","owner":[],"postedDate":"November 6th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":38465194,"name":"Biological sciences/Cancer/Gastrointestinal cancer/Pancreatic cancer"},{"id":38465195,"name":"Health sciences/Medical research/Drug development"},{"id":38465196,"name":"Biological sciences/Immunology/Immunotherapy/Immunization"}],"tags":[],"updatedAt":"2024-12-12T06:55:30+00:00","versionOfRecord":[],"versionCreatedAt":"2024-11-06 07:07:24","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-5183420","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-5183420","identity":"rs-5183420","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}